DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

MgSO4 Combined With Rocuronium Priming

Information source: Seoul National University Bundang Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Muscle Relaxation

Intervention: magnesium sulfate (Drug); priming (Drug); magnesium sulfate and priming (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Seoul National University Bundang Hospital

Official(s) and/or principal investigator(s):
Sanghwan Do, M.D., PH.D., Study Chair, Affiliation: Seoul National University Bundang Hospital

Overall contact:
Mihyun Kim, MD, Phone: 82-31-787-2034, Email: snmd56@yahoo.com


Priming with either rocuronium or MgSO4 is known to accelerate the effect of rocuronium on muscle relaxation. The purpose of this study is to define the effect of MgSO4 on the rocuronium-priming.

Clinical Details

Official title: MgSO4 Combined With Rocuronium Priming

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: time from injection of induction dose of rocuronium until 95% depression of TOF

Secondary outcome:

rocuronium duration

intubating condition

Detailed description: Acceleration of muscle relaxation is beneficial in rapid-sequence intubation. If MgSO4 combined with priming is efficient in accelerating muscle relaxation, it would be an interesting alternative to rapid-sequence intubation.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- patients of ASA Ⅰ-Ⅱ

- aged 18~65

- scheduled to undergo elective surgery under general anesthesia

Exclusion Criteria:

- risk of pulmonary aspiration

- anticipated airway difficulty

- reactive airway disease

- allergic to study drugs

- neuromuscular / cardiovascular/ renal/ hepatic disease

- atrioventricular conduction disturbance

- BMI < 18. 5 or > 24. 9

- chronic treatment with calcium channel blocker

- medications which affect muscle relaxation

Locations and Contacts

Mihyun Kim, MD, Phone: 82-31-787-2034, Email: snmd56@yahoo.com

Seoul national university Bundang hospital, Seongnam, Kyoung-ki-do 463-707, Korea, Republic of; Recruiting
Additional Information

Starting date: May 2011
Last updated: January 6, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017